Osteoporosis International

, Volume 15, Issue 6, pp 452–458 | Cite as

Hip fracture risk in statin users—a population-based Danish case-control study

  • Lars Rejnmark
  • Mette Lena Olsen
  • Søren Paaske Johnsen
  • Peter Vestergaard
  • Henrik Toft Sørensen
  • Leif Mosekilde
Original Article


Based on animal studies, statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have been suggested as potential agents in the treatment of osteoporosis. In some epidemiological studies, statins have been associated with a reduced fracture risk. Our objective was to examine associations between statin treatment and risk of hip fracture in a population-based case-control study. A total of 6660 subjects with hip fracture and 33,274 gender- and age-matched population controls were identified from 1 January 1994 to 31 December 2001 using the Hospital Patient Register in North Jutland County, Denmark, and the Danish Central Personal Registry, respectively. Data on redeemed prescriptions for statins within the last 5 years before the index date were retrieved from a population-based prescription database. We used conditional logistic regression to estimate odds ratios (OR) for hip fracture according to use of statin prescriptions adjusted for potential confounding factors, i.e. gender, other diseases, and use of other drugs known to affect bone metabolism and fracture risk. After adjustment for potential confounders, statin treatment was associated with a reduced risk of hip fracture (OR=0.68; 95% confidence interval: 0.50–0.93) for those who had redeemed more than three prescriptions for a statin drug. We found that risk of hip fracture decreased with the number of statin prescriptions. Stratified analyses on gender and age did not reveal any major differences between men and women or among different age groups on the estimates between use of statins and hip fracture risk. Our findings support an association between statin treatment and a reduced hip fracture risk. However, it is unclear whether this association is causal.


Case-control study Fracture Human Osteoporosis Statins 



This study received financial support from the Western Danish Research Forum for Health Sciences and grants from the Medical Research Council of North Jutland no. 2-16-4-0005-98.


  1. 1.
    Anon (1993) Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646–650PubMedGoogle Scholar
  2. 2.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1341PubMedGoogle Scholar
  3. 3.
    Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946–1949CrossRefPubMedGoogle Scholar
  4. 4.
    Oxlund H, Dalstra M, Andreassen TT (2001) Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 69:299–304PubMedGoogle Scholar
  5. 5.
    Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205–3210PubMedGoogle Scholar
  6. 6.
    Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211–3216PubMedGoogle Scholar
  7. 7.
    Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Int Med 162:537–540CrossRefGoogle Scholar
  8. 8.
    van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850–1855PubMedGoogle Scholar
  9. 9.
    Pedersen TR, Kjekshus J (2000) Statin drugs and the risk of fracture. 4S Study Group. JAMA 284:1921–1922Google Scholar
  10. 10.
    Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357:509–512CrossRefPubMedGoogle Scholar
  11. 11.
    Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46:263–268PubMedGoogle Scholar
  12. 12.
    Wacholder S, McLaughlin JK, Silverman DT, Mandel JS (1992) Selection of controls in case-control studies. I. Principles. Am J Epidemiol 135:1019–1028PubMedGoogle Scholar
  13. 13.
    Nielsen GL, Sorensen HT, Zhou W, Steffensen FH, Olsen J (1997) The pharmacoepidemiologic prescription database of North Jutland—a valid tool in pharmacoepidemiological research. Int J Risk Safety Med 10:203–205Google Scholar
  14. 14.
    Capella D (1993) Descriptive tools and analysis. In: Dukes MNG (ed) Drug utilization studies: methods and uses. WHO Regional Publications, Copenhagen, pp 55–58Google Scholar
  15. 15.
    Schimmer BP, Parker KL (1996) Adrenocorticotropic hormone. In: Hardman JG, Gilman AG, Limbird LE (eds) Goodman & Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 1459–1485Google Scholar
  16. 16.
    Tannirandorn P, Epstein S (2000) Drug-induced bone loss. Osteoporos Int 11:637–659CrossRefPubMedGoogle Scholar
  17. 17.
    Chan KA, Andrade SE, Boles M, Buist DSM, Chase.G.A., Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydromethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185–2188CrossRefPubMedGoogle Scholar
  18. 18.
    Ray WA, Daugherty JR, Griffin MR (2002) Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 8:276–279CrossRefPubMedGoogle Scholar
  19. 19.
    Anon (1980) Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 303:1038–1041PubMedGoogle Scholar
  20. 20.
    Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773PubMedGoogle Scholar
  21. 21.
    Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L (2002) Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 32:581–589CrossRefPubMedGoogle Scholar
  22. 22.
    Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S (2000) Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271:688–692CrossRefPubMedGoogle Scholar
  23. 23.
    Montagnani A, Gonnelli S, Cepollaro C, Pacini S, Campagna MS, Franci MB, Lucani B, Gennari C (2003) Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone 32:427–433CrossRefPubMedGoogle Scholar
  24. 24.
    Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone mineral density in postmenopausal women. Lancet 355:2218–2219CrossRefPubMedGoogle Scholar
  25. 25.
    Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137–1142Google Scholar
  26. 26.
    Sirola J, Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, Saarikoski S (2002) Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537–541PubMedGoogle Scholar
  27. 27.
    Bjarnason NH, Riis BJ, Christiansen C (2001) The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 12:380–384CrossRefPubMedGoogle Scholar
  28. 28.
    Hsia J, Morse M, Levin V (2002) Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598]. BMC Musculoskelet Disord 3:7CrossRefPubMedGoogle Scholar
  29. 29.
    Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW (2001) Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab 86:4556–4559Google Scholar
  30. 30.
    Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, DeBrock J, Ricerca E, Chesnut CH (1993) The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399–1406PubMedGoogle Scholar
  31. 31.
    Kress BC, Mizrahi IA, Armour KW, Marcus R, Emkey RD, Santora AC (1999) Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women. Clin Chem 45:1009–1017PubMedGoogle Scholar
  32. 32.
    Hoidrup S, Gronbaek M, Gottschau A, Lauritzen JB, Schroll M (1999) Alcohol intake, beverage preference, and risk of hip fracture in men and women. Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 149:993–1001PubMedGoogle Scholar
  33. 33.
    Riahi S, Fonager K, Toft E, Hvilsted-Rasmussen L, Bendsen J, Paaske JS, Sorensen HT (2001) Use of lipid-lowering drugs during 1991–98 in Northern Jutland, Denmark. Br J Clin Pharmacol 52:307–311CrossRefPubMedGoogle Scholar
  34. 34.
    Kjekshus J, Pedersen TR (1995) Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 76:64C–68CPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2004

Authors and Affiliations

  • Lars Rejnmark
    • 1
  • Mette Lena Olsen
    • 2
  • Søren Paaske Johnsen
    • 2
  • Peter Vestergaard
    • 1
  • Henrik Toft Sørensen
    • 2
  • Leif Mosekilde
    • 1
  1. 1.Department of Endocrinology and Metabolism C, Aarhus AmtssygehusAarhus University HospitalAarhus CDenmark
  2. 2.Department of Clinical EpidemiologyAarhus University and Aalborg HospitalsDenmark

Personalised recommendations